Home
Aurobindo Pharma Ltd PE Ratio
![Image](/insights/_next/image?url=https%3A%2F%2Fstorage.googleapis.com%2Fassets.cdp.blinkx.in%2FBlinkx_Website%2Ficons%2Faurobindo-pharma-ltd.png&w=128&q=75)
Aurobindo Pharma Ltd
NSE: AUROPHARMA
PE
Key Highlights
- The P/E Ratio of Aurobindo Pharma Ltd is 18.9 as of 12 Feb 15:30 PM .
- The P/E Ratio of Aurobindo Pharma Ltd changed from 8.5 on March 2020 to 20.1 on March 2024 . This represents a CAGR of 18.78% over 5 years.
- The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1145 as of 12 Feb 15:30 .
- The PE Ratio of Pharmaceuticals Industry has changed from 21.0 to 40.0 in 5 years. This represents a CAGR of 13.75%.
- The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 36.9 in 2024.
Historical P/E Ratio of Aurobindo Pharma Ltd
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Historical P/E Ratio of Aurobindo Pharma Ltd
Company Fundamentals for Aurobindo Pharma Ltd
![Image](/insights/_next/image?url=https%3A%2F%2Fstorage.googleapis.com%2Fassets.cdp.blinkx.in%2FBlinkx_Website%2Ficons%2Faurobindo-pharma-ltd.png&w=128&q=75)
Aurobindo Pharma Ltd
NSE: AUROPHARMA
Share Price
Market Price of Aurobindo Pharma Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
Date | |
---|---|
12 Feb 2025 | 1145.2 |
11 Feb 2025 | 1146.8 |
10 Feb 2025 | 1176.8 |
07 Feb 2025 | 1191.7 |
06 Feb 2025 | 1191.5 |
05 Feb 2025 | 1191.85 |
04 Feb 2025 | 1171.2 |
03 Feb 2025 | 1126.95 |
01 Feb 2025 | 1143 |
31 Jan 2025 | 1171.75 |
SWOT Analysis Of Aurobindo Pharma Ltd
BlinkX Score for Aurobindo Pharma Ltd
Asset Value vs Market Value of Aurobindo Pharma Ltd
Market Value
₹ 0
Asset Value
₹ 0
* All values are in ₹ crores
Competitive Comparison of P/E Ratio
Company | Market Cap | PE Ratio |
---|
Aurobindo Pharma Ltd | 67101 | 18.87 |
Sun Pharmaceuticals Industries Ltd | 406363 | 34.5 |
Divis Laboratories Ltd | 158396 | 76.6 |
Cipla Ltd | 117088 | 23.5 |
Torrent Pharmaceuticals Ltd | 103663 | 55.7 |
Dr Reddys Laboratories Ltd | 101458 | 18.9 |
Company | |
---|---|
Aurobindo Pharma Ltd | 67101 |
Sun Pharmaceuticals Industries Ltd | 406363 |
Divis Laboratories Ltd | 158396 |
Cipla Ltd | 117088 |
Torrent Pharmaceuticals Ltd | 103663 |
Dr Reddys Laboratories Ltd | 101458 |
PE Ratio of Aurobindo Pharma Ltd Explained
₹67101
Market cap
₹3491
Earnings
18.9X
PE Ratio
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.
P/E Ratio Formula
P/E ratio = (CMP of share/ Earning per share)
Types of Price to Earning Ratio
1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
PE Ratio of Pharmaceuticals Industry over time
PE Ratio of Top Sectors
Historical Market Cap of Aurobindo Pharma Ltd
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Historical Market Cap of Aurobindo Pharma Ltd
Historical Revenue, EBITDA and Net Profit of Aurobindo Pharma Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Revenue, EBITDA and Net Profit of Aurobindo Pharma Ltd
Revenue
EBITDA
Net Profit
Historical Dividend Payout of Aurobindo Pharma Ltd
Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.
Historical Dividend Payout of Aurobindo Pharma Ltd
About Aurobindo Pharma Ltd
- Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company.
- Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
- APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
- The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
- APL is running with 24 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.
Aurobindo Pharma Ltd News Hub
Aurobindo Pharma tumbles after US FDA issues warning letter to Telangana unit
In May 2024, the United States Food and Drug Administration (US FDA) had conducted an inspection at
Read more
16 Aug 24
Eugia Pharma Specialities receives USFDA warning for Unit III
Aurobindo Pharma announced that the USFDA has issued a warning letter for Unit-III of Eugia Pharma S
Read more
16 Aug 24
Aurobindo Pharma consolidated net profit rises 61.05% in the June 2024 quarter
Net profit of Aurobindo Pharma rose 61.05% to Rs 919.22 crore in the quarter ended June 2024 as agai
Read more
12 Aug 24
Auro Pharma Q3 PAT slides 10% YoY to Rs 846 crore
However, revenue from operations increased 8.53% year on year (YoY) to Rs 7,978.52 crore in the quar
Read more
07 Feb 25